One-year experience with 68Ga-PSMA PET/CT: applications and results in biochemical recurrence of prostate cancer

Abstract Objective: To show the initial (first-year) experience with 68Ga-PSMA PET/CT at a clinic in Brazil. Materials and Methods: Over a one-year period, 96 examinations with 68Ga-PSMA PET/CT (85 related to prostate cancer and 11 related to kidney cancer) were performed in 90 patients. Results: In the prostate and kidney cancer patients alike, the main clinical indication for 68Ga-PSMA PET/CT was suspicion of recurrence during follow-up (in 65.8% and 63.0% of the cases, respectively). Among the prostate cancer patients, 38.5% of those with a prostate specific antigen (PSA) < 0.5 ng/mL tested positive for recurrence on 68Ga-PSMA PET/CT, compared with 71.0% of those with a PSA of 0.5-0.99, 85.7% of those with a PSA of 1.0-1.99, and 92.6% of those with a PSA > 1.99. Conclusion: Although 68Ga-PSMA PET/CT is a technique that has only recently been applied in clinical settings, despite its high cost, 68Ga-PSMA PET/CT shows great promise as a tool in the clinical management of patients with kidney and prostate cancer, especially in those with prostate cancer whose PSA levels are elevated even after treatment.

Download Full-text

The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels

Nuclear Medicine Communications ◽

10.1097/mnm.0000000000000617 ◽

2017 ◽

Vol 38 (2) ◽

pp. 149-155 ◽

Cited By ~ 19

Author(s):

Levent Kabasakal ◽

Emre Demirci ◽

Jamal Nematyazar ◽

Reşit Akyel ◽

Baresh Razavi ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Ct Imaging ◽

Psma Pet ◽

Pet Ct

Download Full-text

Interim PSMA PET/CT Response Is Predictive of Survival of Prostate Cancer Patients Treatedwith Lu-177 PSMA DKFZ 617

10.1055/s-0040-1708395 ◽

2020 ◽

Author(s):

V Prasad ◽

K Huang ◽

N Czech ◽

S Prasad ◽

MR Makowski ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Psma Pet ◽

Pet Ct

Download Full-text

Faculty Opinions recommendation of Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726129005.793514252 ◽

2016 ◽

Author(s):

Badrinath Konety

Keyword(s):

Prostate Cancer ◽

Targeted Therapy ◽

Cancer Patients ◽

Curative Treatment ◽

Prospective Comparison ◽

Psma Pet ◽

Pet Ct

Download Full-text

Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis

Clinical Chemistry and Laboratory Medicine (CCLM) ◽

10.1515/cclm-2013-0675 ◽

2014 ◽

Vol 52 (5) ◽

Cited By ~ 64

Author(s):

Giorgio Treglia ◽

Luca Ceriani ◽

Ramin Sadeghi ◽

Giampiero Giovacchini ◽

Luca Giovanella

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Detection Rate ◽

Meta Analysis ◽

Specific Antigen ◽

Choline Pet ◽

Pet Ct

Download Full-text

Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence

Nuclear Medicine Communications ◽

10.1097/mnm.0000000000001459 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Berna Okudan ◽

Nazim Coşkun ◽

Bedri Seven ◽

Merve Ağcioğlu Atalay ◽

Aslihan Yildirim ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Biochemical Recurrence ◽

Psma Pet ◽

Pet Ct

Download Full-text

68Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy

Journal of Nuclear Medicine ◽

10.2967/jnumed.121.263006 ◽

2021 ◽

pp. jnumed.121.263006

Author(s):

Qaid Ahmed Shagera ◽

Carlos Artigas ◽

Ioannis Karfis ◽

Gabriela Critchi ◽

Nieves Martinez Chanza ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Metastatic Prostate Cancer ◽

Outcome Prediction ◽

Response Assessment ◽

Psma Pet ◽

Pet Ct

Download Full-text

Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact

Cancers ◽

10.3390/cancers13194982 ◽

2021 ◽

Vol 13 (19) ◽

pp. 4982

Author(s):

Carlos Artigas ◽

Romain Diamand ◽

Qaid Ahmed Shagera ◽

Nicolas Plouznikoff ◽

Fabrice Fokoue ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Predictive Factors ◽

Clinical Management ◽

Biochemical Recurrence ◽

Oligometastatic Disease ◽

Psma Pet ◽

Pet Ct ◽

Hormone Sensitive

Metastasis-directed therapy (MDT) in oligometastatic prostate cancer has the potential of delaying the start of androgen deprivation therapy (ADT) and disease progression. We aimed to analyze the efficacy of PSMA-PET/CT in detecting oligometastatic disease (OMD), to look for predictive factors of OMD, and to evaluate the impact of PSMA-PET/CT findings on clinical management. We retrospectively analyzed a homogeneous population of 196 hormone-sensitive prostate cancer patients (HSPC), considered potential candidates for MDT, with a PSMA-PET/CT performed at biochemical recurrence (BCR) after radical prostatectomy (RP). Multivariable logistic regression analysis was performed based on several clinico-pathological factors. Changes in clinical management before and after PSMA-PET/CT were analyzed. The OMD detection rate was 44% for a total positivity rate of 60%. PSMA-PET/CT positivity was independently related to PSA (OR (95%CI), p) (1.7 (1.3–2.3), p < 0.0001) and PSAdt (0.4 (0.2–0.8), p = 0.013), and OMD detection was independently related to PSA (1.6 (1.2–2.2), p = 0.001) and no previous salvage therapy (0.3 (0.1–0.9), p = 0.038). A treatment change was observed in 58% of patients, mostly to perform MDT after OMD detection (60% of changes). This study showed that PSMA-PET/CT is an excellent imaging technique to detect OMD early in HSPC patients with BCR after RP, changing therapeutic management mostly into MDT.

Download Full-text

Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse

Scientific Reports ◽

10.1038/s41598-020-61910-6 ◽

2020 ◽

Vol 10 (1) ◽

Cited By ~ 2

Author(s):

Naresh Regula ◽

Vasileios Kostaras ◽

Silvia Johansson ◽

Carlos Trampal ◽

Elin Lindström ◽

...

Keyword(s):

Prostate Cancer ◽

Specific Antigen ◽

Anatomical Location ◽

Curative Therapy ◽

Psa Relapse ◽

Positron Emission ◽

Psma Pet ◽

Pet Ct ◽

Prostate Cancer Relapse ◽

Identical Number

AbstractPositron emission tomography (PET) imaging is used to localize recurrent disease in prostate cancer (PCa). The tracer 68Ga-PSMA-11 visualizes lesions overexpressing prostate-specific membrane antigen (PSMA), while 11C-acetate visualizes lesions with increased anabolic metabolism. The aim of this study was to compare the performance of PSMA-PET and acetate-PET in re-staging patients with biochemical relapse. Thirty PCa patients with prostate-specific antigen (PSA) relapse after primary curative therapy were prospectively evaluated. PET/CT examinations using 11C-acetate and 68Ga-PSMA-11 were performed. Identified lesions were categorized according to anatomical location and PET measurements were correlated with PSA at time of scan. Tumour lesions showed higher semi-quantitative uptake values on PSMA-PET than acetate-PET. PSMA-PET identified more lesions in 11 patients, fewer lesions in eight patients, and identical number of lesions in 11 patients. This study indicates better diagnostic performance of PSMA-PET, particularly in detecting lymph node (81% vs 60%, p = 0.02) and bone metastasis (95% vs 61%, p = 0.0001) compared to acetate-PET. However, 38% of PSMA-expressing metastases appear to be metabolically inactive and 15% of metabolically active metastases lack PSMA expression. Addition of PET with a metabolic tracer, such as 11C-acetate, might be beneficial before making treatment decisions.

Download Full-text